



# Oxlumo in the UAE

*The MoHAP named-patient coordination pathway — indicative 2026*

RARE DISEASE · PRIMARY HYPEROXALURIA TYPE 1

## The clinical situation

Oxlumo (lumasiran) is a subcutaneous GalNAC-conjugated siRNA targeting hepatic hydroxyacid oxidase 1 (HAO1) mRNA, FDA-approved for primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate in paediatric and adult patients. Manufactured by Alnylam. Administration is a weight-based subcutaneous injection monthly for three loading doses, then every three months (or monthly in small children). Pre-treatment workup covers PH1 genetic confirmation (AGXT), urine oxalate/creatinine ratio, eGFR, and hydration counselling per FDA labelling.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your nephrologist or metabolic-genetics physician documents PH1 diagnosis, AGXT genotype, oxalate burden, and Oxlumo rationale.
- 2 Baseline workup.** Urine oxalate, eGFR, imaging for nephrocalcinosis, hydration plan per FDA labelling.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, weight-based dosing plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with cold-chain 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the pre-filled syringe; subcutaneous administration arranged with the treating physician.

### Indicative economics

**Reference US cash-pay range:** USD 490,000–530,000 per year of Oxlumo (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody from Alnylam authorised distribution.

**Documentation.** Physician kit tailored to MoHAP review, with AGXT-genetic confirmation and weight-based dosing annex.

**Logistics.** Cold-chain 2–8°C internationally tracked shipment with temperature excursion log. **Concierge case lead.** Named point of contact for family and physician through loading-phase and maintenance cycles. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Oxlumo × UAE first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/oxlumo-uae.html](https://reservemed.com/access-guides/oxlumo-uae.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team